AVALANCHE BIOTECHNOLOGIES, INC. WARRANT TO PURCHASE SERIES A PREFERRED STOCKWarrant Agreement • May 30th, 2014 • Avalanche Biotechnologies, Inc. • Biological products, (no disgnostic substances) • California
Contract Type FiledMay 30th, 2014 Company Industry JurisdictionTHIS CERTIFIES THAT, for value received, , an individual residing at , or assigns (the “Holder”), is entitled to subscribe for and purchase at the Exercise Price (defined below) from AVALANCHE BIOTECHNOLOGIES, INC., a Delaware corporation, with its principal office at 2749 Carolina Avenue, Redwood City, CA 94061 (the “Company”) up to [ ( )] shares of the Series A Stock of the Company (the “Preferred Stock”).
QUARK PHARMACEUTICALS, INC. WARRANT TO PURCHASE SERIES H PREFERRED STOCKWarrant Agreement • September 24th, 2010 • Quark Pharmaceuticals Inc • Pharmaceutical preparations • California
Contract Type FiledSeptember 24th, 2010 Company Industry JurisdictionThis Certifies That, for value received, «WarrantHolder», or assigns (the “Holder”), is entitled to subscribe for and purchase at the Exercise Price (defined below) from Quark Pharmaceuticals, Inc., a California corporation, with its principal office at 6501 Dumbarton Circle, Fremont, California 94555 (the “Company”) up to «NumberOfShares» shares of the Series H Preferred Stock of the Company (the “Preferred Stock”).
ARYX THERAPEUTICS WARRANT TO PURCHASE SERIES C PREFERRED STOCKWarrant Agreement • August 30th, 2007 • ARYx Therapeutics, Inc. • California
Contract Type FiledAugust 30th, 2007 Company JurisdictionTHIS CERTIFIES THAT, for value received, Life Science Group, Inc., with its principal office at One Soundshore Drive 2/Fl., Greenwich, CT 06830, or assigns (the “Holder” or “Purchaser”), is entitled to subscribe for and purchase at the Exercise Price (defined below) from ARYx Therapeutics, a California corporation, with its principal office at 2255 Martin Avenue, Suite F, Santa Clara, CA 95050 (the “Company”) up to 34,006 shares of Series C Preferred Stock of the Company (the “Preferred Stock”), as provided herein.